pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
SKYRIZI · news · pharmadog
← back to SKYRIZI
News mentioning SKYRIZI
14
stories
7d
6 immunology targets to sustain a mammoth I&I market
biospace
27d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Jul 31, 26
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 29, 26
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Apr 29, 26
AbbVie faces questions about Skyrizi competition from J&J
endpoints
Apr 27, 26
Oruka surges as long-acting psoriasis drug shows early promise
biopharma dive
Apr 27, 26
Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
endpoints
Apr 27, 26
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
stat
